N
Nicholas E. Powers
Researcher at University of Colorado Denver
Publications - 6
Citations - 143
Nicholas E. Powers is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Inflammation & Tumor necrosis factor alpha. The author has an hindex of 3, co-authored 6 publications receiving 29 citations. Previous affiliations of Nicholas E. Powers include University of Colorado Boulder.
Papers
More filters
Journal ArticleDOI
Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion
Isak W. Tengesdal,Isak W. Tengesdal,Dinoop Ravindran Menon,Douglas G. Osborne,Charles Preston Neff,Nicholas E. Powers,Fabia Gamboni,Adolfo G Mauro,Angelo D'Alessandro,Davide Stefanoni,Morkos A. Henen,Morkos A. Henen,Taylor S. Mills,Dennis M. de Graaf,Dennis M. de Graaf,Tania Azam,Beat Vögeli,Brent E. Palmer,Eric M. Pietras,James DeGregori,Aik Choon Tan,Leo A. B. Joosten,Mayumi Fujita,Charles A. Dinarello,Charles A. Dinarello,Carlo Marchetti +25 more
TL;DR: In this paper, the formation of the pyrin domain-containing-3 (NLRP3) inflammasome activation in melanoma is linked to IL-1β production, inflammation, and immunosuppression.
Journal ArticleDOI
Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression.
Isak W. Tengesdal,Isak W. Tengesdal,Alberto Dinarello,Alberto Dinarello,Nicholas E. Powers,Matthew A. Burchill,Leo A. B. Joosten,Carlo Marchetti,Charles A. Dinarello,Charles A. Dinarello +9 more
TL;DR: In this article, a safe-in-humans specific NLRP3 oral inhibitor was used to suppress IL-1β-mediated inflammation by inhibiting the NOD-like receptor protein 3 (NLRP3).
Journal ArticleDOI
Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease.
Dennis M. de Graaf,Dennis M. de Graaf,Ralph J.A. Maas,Ralph J.A. Maas,Sanne P. Smeekens,Sanne P. Smeekens,Elan Z. Eisenmesser,Jasmina S. Redzic,Monique M. Helsen,Nicholas E. Powers,Suzhao Li,Vassili Kalabokis,Mark S. Gresnigt,Mark S. Gresnigt,Leo A. B. Joosten,Leo A. B. Joosten,Leo A. B. Joosten,Charles A. Dinarello,Charles A. Dinarello,Frank L. van de Veerdonk,Frank L. van de Veerdonk +20 more
TL;DR: Overall, IL-38 exhibits broad anti-inflammatory properties in models of systemic and local inflammation and therefore may be an effective cytokine therapy.
Journal ArticleDOI
PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis
Nicholas E. Powers,Benjamin J Swartzwelter,Carlo Marchetti,Dennis M. de Graaf,Dennis M. de Graaf,Alexandra Lerchner,Martin Schlapschy,Rajiv Datar,Uli Binder,Carl K. Edwards,Arne Skerra,Charles A. Dinarello,Charles A. Dinarello +12 more
TL;DR: PAS–IL-1Ra is validated as an active IL-1 antagonist with marked in vivo potency and a significantly extended half-life compared with anakinra.
Journal ArticleDOI
Metabolic Reprogramming of Mouse Bone Marrow Derived Macrophages Following Erythrophagocytosis.
Alexis Catala,Lyla A. Youssef,Julie A. Reisz,Monika Dzieciatkowska,Nicholas E. Powers,Carlo Marchetti,Matthew S. Karafin,James C. Zimring,Krystalyn E. Hudson,Kirk C. Hansen,Steven L. Spitalnik,Angelo D'Alessandro +11 more
TL;DR: It is demonstrated that EP significantly alters amino acid and fatty acid metabolism, the Krebs cycle, OXPHOS, and arachidonate-linoleate metabolism, and modifies macrophage polarization and EP-mediated metabolic reprogramming of BMDMs does not occur following exposure to IgG alone.